Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II double-blind crossover study of trimetazidine in fibromyalgia
2007-001743-21Phase 2Completed
- Sponsor
- Generics
- Start
- Sep 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of trimetazidine in fibromyalgia (FM) (2 arms), sponsored by Generics. Primary endpoint: Change in pain visual analogue score (VAS) from baseline after 10 days of treatment. Started Sep 2007; status: completed.
02
Drugs
trimetazidine
03
Conditions
fibromyalgia (FM)
Beyond the preview
Go deeper on 2007-001743-21.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-001743-21.